linjc16/ctgov huggingface dataset:
Effects of Respiratory Rehabilitation by Gender in COPD Patients

Study Overview
=================
Brief Summary
-----------------
Without calling into question the effectiveness of pulmonary rehabilitation in women, the difference in outcome by gender was not established due to insufficient evidence . Studies demonstrating the effectiveness of pulmonary rehabilitation include a majority of men, which no longer corresponds to the sex ratio of the disease. The impact of gender on pulmonary rehabilitation outcomes was not established due to insufficient evidence.

Official Title
-----------------
Effects of Pulmonary Rehabilitation According to Gender, in COPD Patients

Conditions
-----------------
COPD, Pulmonary Rehabilitation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient > 18 years old No opposition filed Patient with COPD Completed participation in respiratory rehabilitation program Exclusion Criteria: Refusal of participation Patient under tutorship or curatorship No final assessment Patients with sex changes in marital status

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DYSPNEA-12 | Dyspnea-12 allows to evaluate sensori and emotional dyspnea | Change from baseline Dyspnea-12 score at 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, pulmonary rehabilitation, Dyspnea, quality of life
A New Protocol for Continuous Vancomycin Infusion Dosing.

Study Overview
=================
Brief Summary
-----------------
This observational study prospectively collect data on chosen dosing, renal function, measured plasma concentrations and adherence to the recommended clinical protocl for ICU patients treated with continuous vancomycin infusion.

Official Title
-----------------
Evaluation of a New Clinical Protocol for Dose Selection of Vancomycin for Continuous Infusion in ICU Patients.

Conditions
-----------------
Sepsis, Vancomycin Treatment

Intervention / Treatment
-----------------
* Other: Plasma vancoymcin measurements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Start of continuous vancomycin infusion during the course of intensive care and at least one measurement of plasma concentration. Exclusion Criteria: Vancomycin treatment within 96 h before admission to the unit. Vancomycin treatment started with intermittent bolus infusions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Plasma vancoymcin measurements|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time (days) from start of treatment to first measurement of a plasma vancomycin concentration between 20 and 25 mg/mL | The title is a full description. | Until the end of treatment or discharge from unit | 
| Relationship between time to intended concentration (15-20 mg/L) and adherence to the dosing protocol (% complete adherence). | For each patient the actually administired dose of vancomycin will be compared to the recommendation in the dosing protocol. The time to the intended concentration will be compared between patients with 100% adherence to the recommendations and for patients with dosing not following the recommendations. | Until the end of treatment or discharge from unit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of the total treatment duration with the intended plasma concentration 15-20 mg/L. | The title is a full description. | Until the end of treatment or discharge from unit | 
| Relationship between Percentage of the total treatment duration with the intended plasma concentration (15-20 mg/L) and adherence to the dosing protocol. | The title in combination with the description of outcome 2 is a sufficient description. | Until the end of treatment or discharge from unit |
GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry

Study Overview
=================
Brief Summary
-----------------
This is a French Registry mandated by the French National Health Authority assessing long-term (5-years) safety of the GORE® TAG® Thoracic Endoprosthesis treating diseases of the thoracic aorta.

Detailed Description
-----------------
Endovascular therapy to treat thoracic disease seems to provide a plausible benefit compared to surgery in terms of operative mortality and severe morbidity. The French National Health Authority (HAS) requires a 5-year follow-up as part of the renewal of reimbursement for these endoprostheses in order to collect long-term follow-up data under real-life conditions of use.

Official Title
-----------------
Evaluation on the Treatment of Diseases of the Thoracic Aorta With the Thoracic Endoprosthesis GORE® TAG®

Conditions
-----------------
Aortic Aneurysm, Thoracic, Descending Thoracic Aortic Dissection, Aortic Diseases, Aorta Thoracic; Traumatic Rupture, Penetrating Ulcer

Intervention / Treatment
-----------------
* Device: GORE® TAG® Thoracic Endoprostheses


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient where a GORE® TAG® or Conformable GORE® TAG® Thoracic Endoprosthesis is implanted (successfully or not) for the treatment of disease of the descending thoracic aorta. Patient who had previously consented to the collection and processing of personal medical data. Patient older than 18 years at the time of treatment. Exclusion Criteria: Patients who have already received treatment with a thoracic endoprosthesis other than the GORE® TAG® or Conformable GORE® TAG® Thoracic Endoprosthesis and for whom 'revision' or reintervention is required. Patients whose clinical follow-up is not possible (i.e. patients who cannot return for control visits because they live abroad).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: GORE® TAG® Thoracic Endoprostheses|Endovascular therapy to treat thoracic disease|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of long term all-cause mortality |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exclusion rate of aneurysm, penetrating aortic ulcer (PAU), false lumen or site of rupture |  | 5 years | 
| Rate of neurological complications |  | 5 years | 
| Rate of cardiac, renal, and pulmonary complications |  | 5 years | 
| Rate of device-related complications |  | 5 years | 
| Rate of surgical conversion |  | 5 years | 
| Rate of secondary procedures |  | 5 years | 
| Rate of disease related mortality |  | 5 years |
Combined Cataract Surgery and Planned Descemetorhexis

Study Overview
=================
Brief Summary
-----------------
A pilot study designed to assess the feasibility of planned descemetorhexis for the treatment of Fuchs' corneal dystrophy.

Official Title
-----------------
Combined Cataract Surgery and Planned Descemetorhexis

Conditions
-----------------
Fuchs' Corneal Dystrophy, Cataract

Intervention / Treatment
-----------------
* Procedure: Descemetorhexis


Participation Criteria
=================
Eligibility Criteria
-----------------
General Inclusion Criteria: Patient >18 years old Willing and able to provide informed consent Ocular Inclusion Criteria (all ocular inclusion criteria apply only to the study eye): Fuchs' corneal dystrophy diagnosed Cataract present Best corrected visual acuity ≤ 20/40 Candidate for current endothelial transplant procedure (DSAEK, DMEK) General Exclusion Criteria: <18 years old Medically unstable patient Monocular patient Unwilling or unable to provide informed consent Ocular Exclusion Criteria (all ocular exclusion criteria apply only to the study eye): Corneal dystrophy other than Fuchs' Central corneal scar or central opacity not related to Fuchs' Severe nonproliferative diabetic retinopathy or proliferative diabetic retinopathy History of prior vitreoretinal surgery Advanced or unstable glaucoma Known steroid responders with glaucoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Descemetorhexis<br> | Procedure: Descemetorhexis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal clarity as assessed by slit lamp photography |  | Assessed up to 1 year following descemetorhexis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resolution of edema as assessed by slit lamp photography |  | Assessed up to 1 year following descemetorhexis |
A Swedish Questionnaire Study to Investigate the Perception of Menstrual Bleedings

Study Overview
=================
Brief Summary
-----------------
This field based, questionnaire study will document observational data on womens perception of menstrual bleeding in a cross-section of women in Sweden. Each subject will complete the questionnaire at one occasion.

Official Title
-----------------
A Swedish Cross-sectional Study With Questionnaire to Investigate Perception of Menstrual Bleeding

Conditions
-----------------
Menorrhagia

Intervention / Treatment
-----------------
* Behavioral: No drug


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All women 40-45 years available in the web-panel of SIFO Completion of the web-based questionnaire Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Behavioral: No drug<br>* No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of subjectively experienced heavy menstrual bleeding assessed by questionnaire |  | Once at baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Social consequences of heavy menstrual bleedings assessed by questionnaire |  | Once at baseline | 
| Costs; e.g. pads, absence from work, loss of income assessed by questionnaire |  | Once at baseline | 
| The treatments given for heavy menstrual bleedings, as surgery or medication assessed by questionnaire |  | Once at baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Menorrhagia, Heavy menstrual bleeding, Uterine Hemorrhage, Menstruation Disturbancies
High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of two dose schedules of activated recombinant human factor VII in treatment of joint bleeds in haemophilia patients with inhibitors.

Official Title
-----------------
rFVIIa (NovoSeven®) for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors: A Double-blind Study of a Single High Dose Versus Standard Multiple Doses of rFVIIa

Conditions
-----------------
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

Intervention / Treatment
-----------------
* Drug: activated recombinant human factor VII


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed of congenital haemophilia A or B with inhibitors to factor VIII or IX, respectively A history of 3 or more joint bleeds during the last 12 months Exclusion Criteria: Joint bleeding within 7 days prior to trial start Treatment for bleeds within the last 5 days prior to trial start Clinically relevant coagulation disorders other than congenital haemophilia A or B
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: activated recombinant human factor VII|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global treatment response of the patient by an algorithm based pain and joint mobility assessments |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain assessment |  |  | 
| Mobility assessment |  |  | 
| Circumference of joint |  |  | 
| Adverse events |  |  |
Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Dual-energy CT (DECT) provides information on the blood volume in tumors and lymph nodes. As tumors respond to treatment, preliminary data suggests that the blood volumes changes as well. Investigators are therefore using DECT to test whether it can be used on radiation treatment to rapidly assess response to treatment.

Official Title
-----------------
Pilot Study of Dual-Energy Computed Tomography in Stage III Non-Small Cell Lung Cancer

Conditions
-----------------
Non-small Cell Lung Cancer Stage III

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged greater than 18 years with a diagnosis of stage III non-small cell lung cancer. Planned treatment with either definitive chemoradiotherapy or preoperative chemoradiotherapy followed by surgical resection. PET-CT study within 4 weeks of next available DECT study. Patients must have measurable primary and nodal disease, defined by at least one lesion (primary and lymph node) greater than 1 cm. Kidney function sufficient to tolerate iodine-based CT contrast. No allergy to iodine-based contrast. Ability to understand and the willingness to sign informed consent. Exclusion Criteria: Participants with a prior history of thoracic radiotherapy. Participants may not be receiving any other study agents. Inability to tolerate CT contrast Pregnant women are excluded from this study because radiotherapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with radiotherapy, breastfeeding should be discontinued if the mother is treated with radiotherapy. These potential risks may also apply to other agents used in this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the tumor's maximum iodine related attenuation (IRA) from baseline to on-treatment DECT. | This change in the maximum IRA will be compared with the change in the maximum standardized uptake value (SUV max) between baseline PET-CT and follow-up PET-CT at 3 months after treatment. For patients undergoing surgery, this change in the maximum IRA will be compared between patients who have a complete pathologic response, and those patients who do not. | 0, 1, 3, 5 |
GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors

Study Overview
=================
Brief Summary
-----------------
Lung neuroendocrine tumor (LNT) represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker. GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT. The team have assessed the GLUT1 immunohistochemical staining in 36 LNT and to assess its diagnostic value.

Detailed Description
-----------------
The (LNT) Lung neuroendocrine tumor represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker. GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT.

Official Title
-----------------
GLUT1: A Novel Tool Reflecting Proliferative Activity of Lung Neuroendocrine Tumors

Conditions
-----------------
Lung Tumor

Intervention / Treatment
-----------------
* Other: Immunohistochemistry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with neuroendocrine tumors Exclusion Criteria: Patients without neuroendocrine tumors
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Immunohistochemistry|Immunohistochemistry of Glut1 expression was performed in these 36 cases of neuroendocrine tumor.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the GLUT1 | The objective of this study is to assess the GLUT1 staining in cohort of 36 cases of neuroendocrine tumors by immunohistochemistry and to assess its diagnostic interest. | 5years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glut1, biomarkers, diagnosis
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Study Overview
=================
Brief Summary
-----------------
Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.

Detailed Description
-----------------
The COMPLETE registry is a prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices. The registry will enroll newly-diagnosed patients with PTCL treated with a variety of regimens. The COMPLETE registry is designed to better understand PTCL patient characteristics, treatments, and outcomes to help design and understand future clinical trials.

Official Title
-----------------
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Conditions
-----------------
Peripheral T-cell Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL): Aggressive natural killer (NK)-cell leukemia Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+) Angioimmunoblastic T-cell lymphoma Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-) PTCL, not otherwise specified (NOS) T/NK-cell lymphoma, nasal type Enteropathy-type intestinal lymphoma Hepatosplenic T-cell lymphoma Subcutaneous panniculitis T-cell lymphoma Transformed mycosis fungoides (at diagnosis of transformation) T-cell prolymphocytic leukemia (T-PLL) Cutaneous gamma/delta (γ/δ) T-cell lymphoma Cutaneous aggressive CD8+ T-cell lymphoma Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm) Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative disorders of childhood) Other T-Cell lymphomas that are not listed in the Exclusion Criteria Patient gives written informed consent Exclusion Criteria: Patient has other T- or NK-cell malignancies including: Precursor T/NK neoplasms T-cell large granular lymphocytic leukemia Mycosis fungoides, other than transformed mycosis fungoides Sézary syndrome Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-Hodgkins Lymphoma, Non-Hodgkin's Lymphoma, Lymphoma